Literature DB >> 4713634

Variations in the red cells in paroxysmal nocturnal haemoglobinuria.

W F Rosse.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4713634     DOI: 10.1111/j.1365-2141.1973.tb01657.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  23 in total

Review 1.  [Paroxysmal nocturnal hemoglobinuria].

Authors:  P Blaas; S Weber; G M Hänsch; H H Peter
Journal:  Klin Wochenschr       Date:  1990-03-05

2.  Erythrocyte serology of some malignant diseases.

Authors:  G W Bird
Journal:  Blut       Date:  1977-09-29

Review 3.  Pesg PNH diagnosis, follow-up and treatment guidelines.

Authors:  Fahri Sahin; Olga Meltem Akay; Mesut Ayer; Mehmet Sinan Dal; Sehmus Ertop; Osman Ilhan; Volkan Karakus; Mehmet Ali Ozcan; Vildan Ozkocaman; Hayri Ozsan; Ozan Salim; Mahmut Tobu; Anil Tombak; Tulin Firatli Tuglular; Mehmet Yilmaz; Ali Unal; Mustafa Nuri Yenerel; Guray Saydam
Journal:  Am J Blood Res       Date:  2016-08-05

4.  Mechanisms of immune lysis of the red cells in hereditary erythroblastic multinuclearity with a positive acidified serum test and paroxysmal nocturnal hemoglobinuria.

Authors:  W F Rosse; G L Logue; J Adams; J H Crookston
Journal:  J Clin Invest       Date:  1974-01       Impact factor: 14.808

5.  The management of paroxysmal nocturnal hemoglobinuria: recent advances in diagnosis and treatment and new hope for patients.

Authors:  Neal S Young; Gabrielle Meyers; Hubert Schrezenmeier; Peter Hillmen; Anita Hill
Journal:  Semin Hematol       Date:  2009-01       Impact factor: 3.851

6.  Complement lysis of human erythrocytes. Differeing susceptibility of two types of paroxysmal nocturnal hemoglobinuria cells to C5b-9.

Authors:  C H Packman; S I Rosenfeld; D E Jenkins; P A Thiem; J P Leddy
Journal:  J Clin Invest       Date:  1979-08       Impact factor: 14.808

7.  Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor.

Authors:  A Nicholson-Weller; J P March; S I Rosenfeld; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1983-08       Impact factor: 11.205

8.  Characterization of alternative pathway inhibition by a serum derived, low molecular weight complement inhibitor.

Authors:  P J Baker; C J Parker; S G Osofsky
Journal:  Clin Exp Immunol       Date:  1984-01       Impact factor: 4.330

9.  Paroxysmal nocturnal hemoglobinuria type III. Lack of an erythrocyte membrane protein restricting the lysis by C5b-9.

Authors:  G M Hänsch; S Schönermark; D Roelcke
Journal:  J Clin Invest       Date:  1987-07       Impact factor: 14.808

10.  The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab.

Authors:  Richard Kelly; Stephen Richards; Peter Hillmen; Anita Hill
Journal:  Ther Clin Risk Manag       Date:  2009       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.